{"entity":{"id":"nct04619004","kind":"trial","name":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","aka":["HERTHENA-Lung01"],"tldr":"A phase 2 trial of Patritumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.","summary":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT04619004 by Daiichi Sankyo, with 277 participants enrolled, started 2021-02-02 and due to reach its primary completion in 2022-11-21. Interventions recorded: Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration). Conditions listed: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04619004","url":"https://clinicaltrials.gov/study/NCT04619004"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["patritumab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04619004-j-clin-oncol-2023"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04619004","phase":"2","setting":"HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Daiichi Sankyo","started":"2021-02-02","startedType":"actual","yearReported":2024,"enrolled":277,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)","primary":true,"unit":"participants","arms":[{"name":"Patritumab Deruxtecan 5.6 mg/kg","n":225,"value":64,"note":"Figures from the ClinicalTrials.gov results section (first posted 2024-04-02), not from a publication"},{"name":"Patritumab Deruxtecan Up-Titration","n":50,"value":8}],"source":"https://clinicaltrials.gov/study/NCT04619004?tab=results"}]},"route":"/trials/nct04619004/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}],"paper":[{"id":"paper-nct04619004-j-clin-oncol-2023","kind":"paper","name":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","route":"/key-papers/paper-nct04619004-j-clin-oncol-2023/"}]}}